These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32493385)

  • 1. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases.
    Lanar S; Acquadro C; Seaton J; Savre I; Arnould B
    Orphanet J Rare Dis; 2020 Jun; 15(1):134. PubMed ID: 32493385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.
    Hong YD; Villalonga-Olives E; Perfetto EM
    Value Health; 2019 Aug; 22(8):925-930. PubMed ID: 31426934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
    ; ;
    Health Qual Life Outcomes; 2006 Oct; 4():79. PubMed ID: 17034633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do patients and other members of the public engage with the orphan drug development? A narrative qualitative synthesis.
    Frost J; Hall A; Taylor E; Lines S; Mandizha J; Pope C
    Orphanet J Rare Dis; 2023 Apr; 18(1):84. PubMed ID: 37069597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?
    Menon D; Stafinski T; Dunn A; Short H
    Patient; 2015 Feb; 8(1):29-39. PubMed ID: 25516506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
    Maeda K; Kaneko M; Narukawa M; Arato T
    Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.
    Banerjee AK; Okun S; Edwards IR; Wicks P; Smith MY; Mayall SJ; Flamion B; Cleeland C; Basch E;
    Drug Saf; 2013 Dec; 36(12):1129-49. PubMed ID: 24092596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T; Jürges H; Michaeli DT
    BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
    Winstone J; Chadda S; Ralston S; Sajosi P
    Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
    Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
    Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.
    Gnanasakthy A; Lewis S; Clark M; Mordin M; DeMuro C
    Health Qual Life Outcomes; 2013 May; 11():83. PubMed ID: 23675876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal and regulatory aspects of orphan drugs.
    Shani S; Yahalom Z
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
    Joppi R; Bertele' V; Garattini S
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and trend of clinical development of orphan drugs in China.
    Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
    Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.